GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lukas Biomedical Inc (ROCO:6814) » Definitions » EV-to-Revenue

Lukas Biomedical (ROCO:6814) EV-to-Revenue : 12.70 (As of Sep. 26, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Lukas Biomedical EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Lukas Biomedical's enterprise value is NT$1,237.62 Mil. Lukas Biomedical's Revenue for the trailing twelve months (TTM) ended in Jun. 2024 was NT$97.42 Mil. Therefore, Lukas Biomedical's EV-to-Revenue for today is 12.70.

The historical rank and industry rank for Lukas Biomedical's EV-to-Revenue or its related term are showing as below:

ROCO:6814' s EV-to-Revenue Range Over the Past 10 Years
Min: 5.79   Med: 7.46   Max: 12.91
Current: 12.71

During the past 5 years, the highest EV-to-Revenue of Lukas Biomedical was 12.91. The lowest was 5.79. And the median was 7.46.

ROCO:6814's EV-to-Revenue is ranked worse than
60.21% of 1043 companies
in the Biotechnology industry
Industry Median: 7.51 vs ROCO:6814: 12.71

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-09-26), Lukas Biomedical's stock price is NT$29.60. Lukas Biomedical's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was NT$2.62. Therefore, Lukas Biomedical's PS Ratio for today is 11.32.


Lukas Biomedical EV-to-Revenue Historical Data

The historical data trend for Lukas Biomedical's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lukas Biomedical EV-to-Revenue Chart

Lukas Biomedical Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-Revenue
- - 10.65 9.71 6.68

Lukas Biomedical Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Jun24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 9.71 - 6.68 - -

Competitive Comparison of Lukas Biomedical's EV-to-Revenue

For the Biotechnology subindustry, Lukas Biomedical's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lukas Biomedical's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lukas Biomedical's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Lukas Biomedical's EV-to-Revenue falls into.



Lukas Biomedical EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Lukas Biomedical's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=1237.619/97.424
=12.70

Lukas Biomedical's current Enterprise Value is NT$1,237.62 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Lukas Biomedical's Revenue for the trailing twelve months (TTM) ended in Jun. 2024 was NT$97.42 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lukas Biomedical  (ROCO:6814) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Lukas Biomedical's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=29.60/2.615
=11.32

Lukas Biomedical's share price for today is NT$29.60.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Jun. 2024 was NT$2.62.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lukas Biomedical EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Lukas Biomedical's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Lukas Biomedical Business Description

Traded in Other Exchanges
N/A
Address
Xinyi Road, Da'an District, 3rd Floor, No. 2, Lane 265, Section 4, Taipei, TWN
Lukas Biomedical Inc is engaged in the research and development of immunotherapy for cancer treatment technologies. It researches on the Memory T cell (LuLym-T) to improve the clinical outcome of cancer treatment.

Lukas Biomedical Headlines

No Headlines